Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead 4Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

4Q Revenues: $1.4 billion (+30%)
 
4Q Earnings: $568.2 million (+41%)
 
FY Revenues: $5.3 billion (+26%)
 
FY Earnings: $2.0 billion (+25%)
 
Comments: Product sales increased 35% to a record $1.4 billion in the quarter and for the year product sales were up 36% to $5.08 billion, driven primarily by Gilead’s antiviral franchise, and growth in sales of Atripla and Truvada. Antiviral product sales were up 35% to $1.3 billion in the quarter and increased 36% to $4.67 billion for the year. Truvada sales increased 25% to $562.1 million in the quarter and increased 33% to $2.1 billion for the year. Atripla sales were up 79% to $465.5 million in the quarter and increased 74% to $1.6 billion for the year. Sales of pulmonary arterial hypertension drug Letairis were $36.2 million in the quarter, up from $14.8 million in 4Q07; and for the year, sales were $112.9 million compared to $21.0 million in 2007. Royalty, contract and other revenues were $40.4 million in the quarter, down 41% and for the year were $251.0 million, down 49% due to lower Tamiflu royalties from Roche.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters